← Leaderboards
Kumaril Bhargava
Catalyst, Llc
$997,022
Attributed
$997,022
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $725.1K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$997,022 · 3
By mechanism
R43$612,604 · 2
R41$384,418 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Pain”
- Emer Leahy · Psychogenics, Inc.$49,781,254
- Lynn Larson Debar · Kaiser Foundation Research Institute$37,527,482
- J Richard Landis · University Of Pennsylvania$34,799,488
- Clifford J Woolf · Boston Children'S Hospital$30,992,766
- Emeran A Mayer · University Of California Los Angeles$29,229,798
- Pamela Susan Douglas · Duke University$28,862,172
Research focus
PainPharmaceutical PreparationsPhase I Clinical TrialsInnovationDoseLegal PatentLeadTopical ApplicationClinical TrialsInflammationSmall MoleculeCellsMilitary PersonnelChronicAgonistCorneaMolecularInjuryAffectAnimalsHospitalsAnimal ModelDrug FormulationsAnalgesics
Grant awards (7)
Topical treatment for burn pain by blocking cutaneous pain receptors.$6,500
R43 · FY2025 · GM · contact PI
Validating SER-014, a TRPV1 antagonist, to treat endometriosis$384,418
R41 · FY2024 · HD · contact PI
Topical treatment for burn pain by blocking cutaneous pain receptors.$340,685
R43 · FY2024 · GM · contact PI
Ocular Formulation Development of Innovative Novel Compounds with superior ocular$25,000
R43 · FY2015 · EY · contact PI
Ocular Formulation Development of Innovative Novel Compounds with superior ocular$122,920
R43 · FY2014 · EY · contact PI
Ocular Formulation Development of Innovative Novel Compounds with superior ocular$92,499
R43 · FY2014 · EY · contact PI
Ocular Formulation Development of Innovative Novel Compounds with superior ocular$25,000
R43 · FY2014 · EY · contact PI